Benitec Biopharma Inc. SEC filings BNTC
Benitec Biopharma Inc. has 334 filings in SEC EDGAR's recent list, going back to Apr 15, 2020. Its latest annual report, Form 10-K, was filed on Sep 14, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 14, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (regulation fd disclosure). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 21, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2026 | — |
| CORRESP | Letter to the SEC | Mar 20, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2026 | — |
| EFFECT | Filing | Feb 10, 2026 | — |
| CORRESP | Letter to the SEC | Feb 6, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2026 | — |
| EFFECT | Filing | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2025 | — |
| EFFECT | Filing | Jun 2, 2025 | — |
| CORRESP | Letter to the SEC | May 29, 2025 | — |
| UPLOAD | Letter from the SEC | May 29, 2025 | — |
| EFFECT | Filing | Nov 12, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2024 | — |
| EFFECT | Filing | May 28, 2024 | — |
| CORRESP | Letter to the SEC | May 23, 2024 | — |
| UPLOAD | Letter from the SEC | May 22, 2024 | — |
| D | Filing | Apr 25, 2024 | — |
| EFFECT | Filing | Mar 5, 2024 | — |
| CORRESP | Letter to the SEC | Mar 1, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 28, 2024 | — |
| DEL AM | Filing | Feb 26, 2024 | — |
| EFFECT | Filing | Aug 8, 2023 | — |
| CORRESP | Letter to the SEC | Aug 3, 2023 | — |
| CORRESP | Letter to the SEC | Aug 3, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2023 | — |
| EFFECT | Filing | Dec 19, 2022 | — |
| CORRESP | Letter to the SEC | Dec 15, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2022 | — |
| EFFECT | Filing | Sep 12, 2022 | — |
| CORRESP | Letter to the SEC | Sep 8, 2022 | — |
| CORRESP | Letter to the SEC | Sep 8, 2022 | — |
| CORRESP | Letter to the SEC | Aug 11, 2022 | — |
| CORRESP | Letter to the SEC | Aug 8, 2022 | — |
| CORRESP | Letter to the SEC | Aug 8, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2022 | — |
| EFFECT | Filing | Feb 26, 2021 | — |
| CORRESP | Letter to the SEC | Feb 25, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2021 | — |
| EFFECT | Filing | Oct 2, 2020 | — |
| CORRESP | Letter to the SEC | Oct 1, 2020 | — |
| CORRESP | Letter to the SEC | Oct 1, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 24, 2020 | — |
| 8-K12B | Filing | Apr 15, 2020 | Apr 15, 2020 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BNTC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1808898
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.